You are here

Article info

Article menu
Download PDFPDF
Original research
US Food and Drug Administration regulatory reviewer disagreements and postmarket safety actions among new therapeutics

Authors

  1. Correspondence to Matthew Herder, Dalhousie University, Halifax, Nova Scotia, B3H 4R2, Canada; matthew.herder{at}dal.ca; Ashley Eadie, Department of Pharmacology, Dalhousie Medicine, Saint John, New Brunswick, Canada; ashley.eadie{at}dal.ca
View Full Text

Citation

Eadie A, MacGregor A, Wallach J, et al
US Food and Drug Administration regulatory reviewer disagreements and postmarket safety actions among new therapeutics
BMJ Evidence-Based Medicine 2023;28:151-156.

Publication history

  • Accepted December 11, 2022
  • First published March 21, 2023.
Online issue publication 
May 22, 2023

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.